Founded by Jack A. Khattar in 2005, Supernus Pharmaceuticals is a Rockville biopharmaceutical company that develops and commercializes medicines for central nervous system diseases. With more than 30 years of product-development expertise, it uses proprietary technologies and an active clinical pipeline to advance treatments in neurology and psychiatry, while marketing its medicines in the United States through specialty sales forces.
Supernus Compliance Program
compliance_program
HHS-OIG Compliance Program Guidance for Pharmaceutical Manufacturers
compliance_program
PhRMA Code on Interactions with Healthcare Professionals
compliance_program
Axsome Therapeutics, IncFounded in January 2012 by physician Herriot Tabuteau, Axsome Therapeutics is a New York biopharmaceutical company focused on central nervous system conditions with limited treatment options. Its work centers on developing therapies intended to give patients and physicians new approaches where existing care falls short.NEW YORK, NY
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
Perception NeurosciencePerception Neuroscience is a New York City-based clinical-stage biopharmaceutical company developing PCN-101, an R-ketamine compound intended to provide faster-acting treatment options for serious psychiatric disorders. The company holds an exclusive license to intellectual property originating from research at Japan’s Chiba University and has advanced PCN-101 through Phase 1 studies and an FDA-cleared IND into Phase 2 clinical development. Perception is majority-owned by atai Life Sciences and partnered with Otsuka Pharmaceutical on development in Japan.New York, NY
P2D BioscienceP2D Bioscience is a specialty pharmaceutical company developing drug candidates for inflammatory disorders of the central nervous system, with a pipeline aimed at frontotemporal dementia, Alzheimer’s disease and ADHD. Its approach combines targeted phenotypic screening with transgenic preclinical models, while its management brings deep experience in neuroscience, toxicology and early-stage drug development. The company advances candidates through preclinical and early clinical studies before seeking partners for later development and commercialization.CINCINNATI, OH